dihexa promotes synaptogenesis De novo induced by GABA in the developing mouse cortex DIHEXA - Beverly Hills Rejuvenation

doi:10.1056/NEJMoa2502082

Sequential start protocol (adding cagrilintide later) When to use: Already on semaglutide 2.4mg Plateaued on semaglutide alone Want to attribute side effects clearly More conservative approach Phase 1: Semaglutide foundation (weeks 1-20) Standard semaglutide titration to 2.4mg Weeks 1-4: 0.25mg Weeks 5-8: 0.5mg Weeks 9-12: 1.0mg Weeks 13-16: 1.7mg Week 17-20: 2.4mg (stabilize for 4 weeks) Phase 2: Add cagrilintide (week 21 onward) Continue semaglutide 2.4mg weekly Week 21-24: Add cagrilintide 0.6mg weekly Week 25-28: Increase to 1.2mg weekly Week 29-32: Increase to 1.8mg weekly Week 33+: 2.4mg weekly (both at maximum) Sequential protocol comparison: Benefits of sequential: Already accustomed to semaglutide effects Can clearly identify cagrilintide-specific side effects Option to stop cagrilintide if intolerable (keep semaglutide) Less overwhelming overall Good for plateaued semaglutide users Expected additional weight loss: On semaglutide 2.4mg alone: Lost 10-15% already After adding cagrilintide: Additional 5-10% over next 6-12 months Total: 15-25% combined Conservative dosing approach (lower maximum) For GI-sensitive individuals: Reduced target doses: Semaglutide: 1.7-2.0mg weekly (instead of 2.4mg) Cagrilintide: 1.8-2.0mg weekly (instead of 2.4mg) Same titration schedule, lower endpoint Better tolerability Extended titration (20+ weeks to maximum): Stay at each dose level 6 weeks instead of 4 Weeks 1-6: Starting doses Weeks 7-12: First increase Weeks 13-18: Second increase Weeks 19-24: Third increase Week 25+: Target doses Conservative protocol table: When to choose conservative: History of severe nausea on GLP-1s Older age (60+) Multiple medications Concerns about tolerability Budget constraints Don't need maximum possible weight loss Use SeekPeptides to design your personalized CagriSema protocol based on GI tolerance

Further, Tesamorelin's N-terminus is adorned with an acetyl group (CHCO-), a modification that might further amplify the molecule's stability and biological efficacy

[36] [17] Phase 2 data showed dose-dependent weight loss in adults with obesity or overweight without diabetes, and phase 3 ATTAIN studies support clinically meaningful weight reduction in adults with and without type 2 diabetes

It also helps in reversing the imbalance of matrix metalloproteinases (MMP-9) and their inhibitors (TIMP-1), and in preventing epithelial-mesenchymal transition (EMT) through the modulation of Nrf2, NF-B, and TGF-1/Smad2/3 signaling pathways 6

Blood-brain barrier penetration after peripheral administration needs quantification via CSF sampling in primate models before human trials would be justifiable